Significance: This study suggests, for the first time, that TAp63, by increasing the expression of its target genes AMPKα2 and MiRNA-143/145, it may decrease the expression of angiotensin-converting enzyme (ACE). Thereby, it may: (1) decrease blood pressure; and (2) congestive heart failure. Thus, pharmacological formulations encompassing “TAp63 activators“ may be used to treat patients suffering from metabolic diseases, such as high blood pressure and congestive heart failure.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Metabolic diseases: TAp63 increases MiRNA-143/145 levels and decreases angiotensin-converting enzyme (ACE)-expression via up regulation of AMPKα2, 26/March/2015, 10.24, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How TAp63 decreases blood pressure and inhibits congestive heart failure